Diseases affecting the brain and central nervous system represent one of the largest global healthcare challenges and greatest medical needs due to the devastating personal and economic consequences for patients, caregivers and society.

Despite the fact that an estimated 60 million people worldwide suffer from neurodegenerative diseases, a population expected to double every 20 years, there are currently no approved disease-modifying therapies or cures available. These diseases devastate patients and their loved ones.

Yumanity is dedicated to protecting the vitality of the mind. Using innovative technology licensed from Susan Lindquist’s laboratory at MIT’s Whitehead Institute, we are working to identify and develop new, disease-modifying therapies for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis (ALS).

LEARN MORE

LATEST NEWS

August 15, 2017

A pharma executive shows moral leadership: Why Ken Frazier did the right thing

VIEW MORE

January 25, 2017

Yumanity scientific co-founders publish two papers in Cell Systems uncovering a genetic network for Parkinson’s

VIEW MORE

October 27, 2016

Colleague, Friend, and Yumanity co-founder, Susan Lindquist, Passes at 67

VIEW MORE

ARCHIVE